Skip to main content

Peer Review reports

From: Phase 1 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of FCN-159 in adults with neurofibromatosis type 1-related unresectable plexiform neurofibromas

Original Submission
27 Oct 2022 Submitted Original manuscript
18 Nov 2022 Author responded Author comments - Xiaojie Hu
Resubmission - Version 2
18 Nov 2022 Submitted Manuscript version 2
28 Jan 2023 Reviewed Reviewer Report
27 Feb 2023 Reviewed Reviewer Report
1 Mar 2023 Reviewed Reviewer Report
6 Apr 2023 Author responded Author comments - Xiaojie Hu
Resubmission - Version 3
6 Apr 2023 Submitted Manuscript version 3
12 Apr 2023 Reviewed Reviewer Report
15 Apr 2023 Reviewed Reviewer Report
25 Apr 2023 Reviewed Reviewer Report
4 Jun 2023 Author responded Author comments - Xiaojie Hu
Resubmission - Version 4
4 Jun 2023 Submitted Manuscript version 4
Publishing
7 Jun 2023 Editorially accepted
3 Jul 2023 Article published 10.1186/s12916-023-02927-2

You can find further information about peer review here.

Back to article page